Teva Breaks Out OTC Sales Figures In Bid To Play Up Diversification
This article was originally published in The Tan Sheet
Executive Summary
Teva Pharmaceutical Industries reported OTC product sales for the first time Feb. 15. The Jerusalem firm said OTC net revenue was $765 million in 2011, up 54.2% and attributable largely to the acquisition of German firm ratiopharm and the PGT Healthcare joint venture with Procter & Gamble.